F-1/A: Biodexa Pharmaceuticals Files F-1/A for $18M Unit Offering

Biodexa Pharmaceuticals PLC filed an Amendment No. 1 to its F-1 Registration Statement for a best efforts public offering of up to 3,536,345 Units, aiming to raise up to $18.0 million for development programs and working capital.

Summary

• Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs, including familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare/orphan brain cancers.
• The company is conducting a best efforts public offering of up to 3,536,345 Units, each consisting of one American Depositary Share (ADS) and one Series L Warrant, or Pre-Funded Units, consisting of one Pre-Funded Warrant and one Series L Warrant.
• The offering aims to raise up to $18.0 million in gross proceeds, with estimated net proceeds of approximately $15.5 million, assuming all units are sold and excluding proceeds from cash exercise of warrants.
• The assumed combined public offering price is $5.09 per Unit, based on the closing price of Depositary Shares on the NASDAQ Capital Market on December 4, 2025.
• The Series L Warrants have an initial exercise price of 225% of the public offering price and expire in 2.5 years, featuring anti-dilution protections, cashless exercise, and a zero cash exercise price option.
• The zero cash exercise price option allows holders to receive an aggregate number of Depositary Shares equal to twice the number issuable upon cash exercise, without additional cash payment, making it highly unlikely the company will receive cash from warrant exercises.
• The exercise price of Series L Warrants will reset on the 5th and 10th trading days after issuance, subject to floor prices of 50% and 30% of the Latest NASDAQ Closing Price, respectively, potentially increasing the number of issuable shares.
• Pre-Funded Units are offered to purchasers whose beneficial ownership would otherwise exceed 4.99% (or 9.99%) of outstanding Ordinary Shares, with a Pre-Funded Warrant exercise price of $0.0001.
• As of December 1, 2025, there were 68,178,708,922 Ordinary Shares outstanding. If all Ordinary Shares offered were issued, they would represent approximately 98.9% of total outstanding Ordinary Shares.
• The company reported cash and cash equivalents of £2.79 million as of September 30, 2025 (unaudited).
• Key clinical assets include eRapa (a proprietary formulation of rapamycin) for FAP and NMIBC, and tolimidone (a selective activator of lyn kinase) for T1D.
• eRapa received FDA Fast Track designation on February 10, 2025, and European Commission Orphan Drug Designation for FAP on May 12, 2025.
• An additional $3.0 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) was received in May 2025 to support the registrational Phase 3 program of eRapa in FAP, expected to fund substantially all costs.
• The Phase 3 study for eRapa in FAP (168 patients across 30 US/Europe sites) activated its first clinical study site on June 25, 2025, and enrolled the first European patients on December 1, 2025.
• The Phase 2a dose-confirming study for tolimidone in T1D recruited its first patient on June 4, 2025.
• MTX110, a program for aggressive rare/orphan brain cancers, has been de-prioritized due to resource constraints.
• The company has re-positioned itself as a therapeutics company, with its proprietary drug delivery technologies (Q-Sphera, MidaSolve, MidaCore) no longer a key priority for active research and development programs.
• A dispute with a former advisor regarding fees was resolved through a settlement, with a payment made on September 29, 2025.

Sentiment

Score: 3

Explanation: While there are positive clinical developments (Fast Track, Orphan Drug, Phase 3 progress for eRapa), the financial aspects of this offering are highly concerning. The significant dilution, the structure of warrants making cash exercise unlikely, the 'best efforts' nature of the offering, and the going concern warning from auditors indicate substantial financial risk and a challenging capital position. The de-prioritization of MTX110 due to resource constraints further highlights financial pressures.

Positives

• eRapa received FDA Fast Track designation on February 10, 2025, which is intended to facilitate development and expedite review for serious conditions with unmet medical needs.
• eRapa received European Commission Orphan Drug Designation for FAP on May 12, 2025, which, if approved for marketing, will provide 10 years of marketing exclusivity and special incentives.
• An additional $3.0 million grant from CPRIT in May 2025, combined with prior grants and company match, is expected to fund substantially all costs of the Phase 3 eRapa study in FAP.
• The Phase 3 clinical study for eRapa in FAP is actively screening patients, with the first site activated on June 25, 2025, and the first European patients enrolled on December 1, 2025.
• The Phase 2a dose-confirming study for tolimidone in T1D has recruited its first patient on June 4, 2025, marking progress in its development.
• The company has a clear strategic focus on building a balanced portfolio of clinical-stage development assets, ideally with a focus on rare/orphan indications, and aims to develop them to proof-of-concept stage before seeking partners.

Negatives

• MTX110, a program for aggressive rare/orphan brain cancers, has been de-prioritized due to resource constraints, indicating a setback in its development pipeline.
• The company's proprietary drug delivery technologies (Q-Sphera, MidaSolve, MidaCore) are no longer a key priority for active research and development programs, representing a shift away from previously highlighted assets.
• The offering is a 'best efforts' offering with no minimum amount of securities required to be sold, meaning the company may not raise the amount of capital it believes is required for its business plans.
• The Series L Warrants include a zero cash exercise price option and reset provisions, making it highly unlikely the company will receive additional funds from their exercise, leading to significant dilution without corresponding cash inflow.
• The offering could cause the Depositary Share price to decline and potentially fall below NASDAQ's minimum bid price requirement, which could result in delisting.
• The company's pro forma as-adjusted net tangible book value per Depositary Share is expected to decrease from $12.19 to $5.63 after the offering, representing an immediate decrease of $7.19 per Depositary Share for existing shareholders.
• The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, requiring investors to rely solely on share price appreciation for any return on their investment.
• Financial information as of September 30, 2025 (£2.79 million cash) is unaudited and could change, and investors are cautioned not to place undue reliance on it.
• The independent registered public accounting firm's report for the year ended December 31, 2024, contains an explanatory paragraph regarding the company's ability to continue as a going concern, highlighting financial instability.

Risks

• Selling a substantial number of Depositary Shares in this offering could cause the price of Depositary Shares to decline.
• Future equity offerings may cause further dilution to existing shareholders.
• Sales of a substantial number of Depositary Shares in the public markets, or the perception that such sales could occur, could depress the market price of Depositary Shares and impair the company's ability to raise capital through additional equity sales.
• Investors must rely on appreciation of the value of Depositary Shares for any return on their investment, as the company does not currently intend to declare cash dividends in the foreseeable future.
• Management will have broad discretion and flexibility in how the net proceeds from this offering are used, which may not prove effective or align with investor expectations.
• The liquidity and trading volume of Depositary Shares could be low, adversely impacting the trading price and shareholders' ability to obtain liquidity.
• As a 'best efforts' offering, no minimum amount of securities is required to be sold, and the company may not raise the capital required for its business plans, potentially necessitating additional funds that may not be available or available on acceptable terms.
• This offering may result in an immediate trading halt or delisting of Depositary Shares from NASDAQ due to public interest concerns regarding the dilutive nature of the transaction or failure to maintain the minimum bid price requirement.
• The company will likely not receive any additional funds upon the exercise of the Series L Warrants due to the zero cash exercise price option and reset provisions.
• There is no public market for the warrants being offered in this offering, limiting their liquidity and potential for resale.
• Holders of Pre-Funded Warrants and Series L Warrants will have no rights as Depositary Share holders until such warrants are exercised.
• The Pre-Funded Warrants and Series L Warrants are speculative in nature and may not have value if the Depositary Shares do not exceed the exercise price during their exercisable period.
• The terms of the warrants could impede the company's ability to enter into certain transactions or obtain additional financing in the future.
• The company may be required to repurchase Series L Warrants in the event of certain Fundamental Transactions, which could materially adversely affect its financial condition and/or results of operations.
• As a foreign private issuer, the company is exempt from certain SEC rules (e.g., frequent periodic reports, U.S. GAAP, proxy rules, Regulation FD, Section 16 reporting), meaning investors may receive less information than from a U.S. public company.
• The company has elected to follow home country corporate governance practices instead of complying with NASDAQ Listing Rule 5635(d) shareholder approval requirements, and does not intend to seek shareholder approval for the issuance of the Units.
• The independent registered public accounting firm's report for the year ended December 31, 2024, contains an explanatory paragraph regarding the company's ability to continue as a going concern.
• The relevant Secura Bio patents may delay a launch of MTX110 for use in patients with Diffuse Midline Glioma (DMG) should the product receive accelerated approval, which could have a material adverse effect on the business, financial condition, and results of operations.

Future Outlook

The company intends to use the net proceeds from this offering to fund its development programs, for working capital, and other general corporate purposes. The strategic focus is to build a balanced portfolio of clinical-stage development assets, ideally with a focus on rare/orphan indications, and to develop these assets to proof-of-concept stage before seeking partners for later-stage development and commercialization. The company does not intend to establish its own manufacturing capabilities or pay cash dividends on its Ordinary Shares in the foreseeable future.

Management Comments

• We believe it is highly unlikely that a holder of the Series L Warrants would pay an exercise price in cash to receive one Depositary Share when the holder could instead choose the zero cash exercise price option and pay no cash to receive up to 15 Depositary Shares if the exercise price decreases to and equals the floor price at the time of such election.
• As a result, we will likely not receive any additional funds and do not expect to receive any additional funds upon the exercise of the Series L Warrants.
• In early 2023, we decided to re-position the Company as therapeutics (as opposed to drug delivery) company and we began looking for additional assets to complement our MTX110 programs.
• The delivery of proof-of-concept clinical data is the primary focus of our business model going forward.
• Our proprietary drug delivery technologies are no longer a key priority for the Company.
• Our aim is to develop our clinical assets to proof-of-concept stage before securing partners to undertake the most expensive, later stage development.
• We do not intend to establish our own manufacturing capabilities.
• Once proof-of-concept has been established, we intend to seek to license our products to a partner who would complete the development, and subsequently market and sale, of the product in an agreed upon licensed territory.
• We view MTX110 as an important asset and we continue to enjoy freedom to use panobinostat for research purposes and we plan to continue to pursue development of MTX110.

Industry Context

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Biodexa's strategic pivot from drug delivery technologies to a focus on clinical-stage therapeutics, particularly in rare/orphan indications, aligns with a trend where such designations (e.g., FDA Fast Track, EU Orphan Drug status) can provide regulatory advantages and market exclusivity, potentially mitigating some development risks. The reliance on non-dilutive grants (like CPRIT and NCI) for funding clinical trials is a common strategy for smaller biotechs to finance expensive development stages without immediate equity dilution. The stated intention to develop assets to proof-of-concept before seeking partners for later-stage development and commercialization is also a standard de-risking approach in the sector, allowing larger pharmaceutical companies to acquire or license assets with demonstrated clinical efficacy.

Comparison to Industry Standards

• The company's strategy to develop assets to proof-of-concept before seeking partners is a common de-risking strategy in the biopharmaceutical industry, allowing larger pharmaceutical companies to acquire or license assets with demonstrated clinical efficacy.
• The receipt of FDA Fast Track and EU Orphan Drug Designation for eRapa aligns with industry best practices for accelerating development and gaining market advantages for drugs addressing unmet medical needs in rare diseases.
• The funding model, relying on non-dilutive grants (e.g., CPRIT, NCI) for clinical trials, is a standard approach for smaller biotechs to finance expensive development stages without immediate equity dilution, similar to how many emerging biopharma companies manage early-stage funding.
• The de-prioritization of MTX110 due to resource constraints is a common challenge in the capital-intensive biotech sector, where companies must make strategic decisions to focus limited resources on the most promising assets.

Corporate Governance

Legal Proceedings

• A dispute with a former advisor regarding fees was resolved through a settlement, with a payment made to the former advisor on September 29, 2025.

Stakeholder Impact

• Shareholders: Face significant dilution from the current offering, especially due to the structure of Series L Warrants which are unlikely to generate cash proceeds upon exercise. There is a potential for share price decline and delisting risk from NASDAQ. No cash dividends are anticipated in the foreseeable future.
• New Investors: Have the opportunity to invest in a clinical-stage biopharmaceutical company with assets targeting rare/orphan diseases, but will experience immediate dilution and are exposed to the financial risks associated with the offering structure and the company's 'going concern' status.
• Employees: Continued employment and potential for equity incentives are contingent on the company's ability to successfully raise capital and advance its pipeline.
• Creditors: The capital raise could provide some liquidity, but the 'going concern' warning from auditors indicates ongoing financial risk and potential challenges in meeting obligations.
• Patients: The continued development of eRapa for FAP and NMIBC, and tolimidone for T1D, offers potential new treatment options for diseases with unmet medical needs, representing a positive impact on patient populations.

Next Steps

• Complete the current public offering of Units and Pre-Funded Units.
• Continue enrolling patients in the Phase 3 eRapa study for FAP in the US and Europe.
• Continue the Phase 2 study of eRapa in NMIBC (Investigator Initiated Trial).
• Continue the Phase 2a dose confirming study for tolimidone in T1D.
• Seek partners for later-stage development and commercialization of clinical assets once proof-of-concept is established.
• File the Annual Report on Form 20-F for the year ended December 31, 2025, which will include complete annual results.

Key Dates

Recommendation

The offering presents significant red flags for investors. The highly dilutive nature of the Series L Warrants, with a zero cash exercise price option and reset provisions, means the company is unlikely to receive substantial cash from their exercise, exacerbating dilution without a corresponding capital inflow. The 'best efforts' nature of the offering provides no assurance of raising the targeted capital. Furthermore, the immediate decrease in net tangible book value per Depositary Share for existing shareholders is substantial. The explicit 'going concern' warning from auditors, coupled with the de-prioritization of a clinical asset (MTX110) due to resource constraints, points to severe financial distress. While clinical progress for eRapa and tolimidone is positive, the financial structure of this capital raise appears highly unfavorable to current and prospective equity holders, suggesting a high risk of further value erosion.

Keywords

Biodexa Pharmaceuticals, BDRX, Public Offering, Units, American Depositary Shares, Warrants, Series L Warrants, Pre-Funded Warrants, Biopharmaceutical, Clinical Stage, eRapa, Rapamycin, FAP, Familial Adenomatous Polyposis, NMIBC, Non-Muscle Invasive Bladder Cancer, Tolimidone, Type 1 Diabetes, T1D, MTX110, Brain Cancer, Orphan Drug Designation, Fast Track Designation, CPRIT Grant, NASDAQ Capital Market, Dilution, Capital Raise, Drug Development, Clinical Trials, Corporate Governance, Foreign Private Issuer, SEC Filing, F-1/A